Erich and Hanna Klessmann Institute, Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Centre NRW, Georgstrasse 11, D-32545 Bad Oeynhausen, Germany.
Center for Biotechnology (CeBiTec), Bielefeld University, 33615 Bielefeld, Germany.
Genes (Basel). 2020 Nov 28;11(12):1430. doi: 10.3390/genes11121430.
Cardiovascular diseases are the number one cause of morbidity and mortality worldwide, but the underlying molecular mechanisms remain not well understood. Cardiomyopathies are primary diseases of the heart muscle and contribute to high rates of heart failure and sudden cardiac deaths. Here, we distinguished four different genetic cardiomyopathies based on gene expression signatures. In this study, RNA-Sequencing was used to identify gene expression signatures in myocardial tissue of cardiomyopathy patients in comparison to non-failing human hearts. Therefore, expression differences between patients with specific affected genes, namely (lamin A/C), (RNA binding motif protein 20), (titin) and (plakophilin 2) were investigated. We identified genotype-specific differences in regulated pathways, Gene Ontology (GO) terms as well as gene groups like secreted or regulatory proteins and potential candidate drug targets revealing specific molecular pathomechanisms for the four subtypes of genetic cardiomyopathies. Some regulated pathways are common between patients with mutations in and as the splice factor RBM20 targets amongst other genes , leading to a similar response on pathway level, even though many differentially expressed genes (DEGs) still differ between both sample types. The myocardium of patients with mutations in is widely associated with upregulated genes/pathways involved in immune response, whereas mutations in lead to a downregulation of genes of the extracellular matrix. Our results contribute to further understanding of the underlying molecular pathomechanisms aiming for novel and better treatment of genetic cardiomyopathies.
心血管疾病是全球发病率和死亡率的首要原因,但潜在的分子机制仍未得到很好的理解。心肌病是心肌的原发性疾病,导致心力衰竭和心脏性猝死的发生率居高不下。在这里,我们根据基因表达特征将四种不同的遗传性心肌病区分开来。在这项研究中,我们使用 RNA 测序来比较心力衰竭患者和非衰竭人类心脏的心肌组织中的基因表达特征。因此,我们研究了特定受影响基因(即 lamin A/C、RNA 结合基序蛋白 20、titin 和 plakophilin 2)的患者之间的表达差异。我们确定了受调控途径、基因本体论 (GO) 术语以及分泌蛋白或调节蛋白等基因组之间的基因型特异性差异,以及潜在的候选药物靶点,揭示了四种遗传性心肌病亚型的特定分子病理机制。一些受调控的途径在 RBM20 等基因的剪接因子突变的患者和 中是共同的,导致即使在两种样本类型之间仍存在许多差异表达基因(DEGs),但在通路水平上仍存在相似的反应。携带 突变的患者的心肌与涉及免疫反应的上调基因/途径广泛相关,而 突变则导致细胞外基质基因的下调。我们的研究结果有助于进一步了解潜在的分子病理机制,旨在为遗传性心肌病的治疗提供新的更好的方法。